Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

BACKGROUND AND AIMS: Infliximab attenuates serological responses to SARS-CoV-2 infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences serological responses, remains unknown. METHODS: Seroprevalence and the magnitude of SARS-CoV-2 nucleocapsid antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Chanchlani, Neil, Lin, Simeng, Chee, Desmond, Hamilton, Benjamin, Nice, Rachel, Arkir, Zehra, Bewshea, Claire, Cipriano, Bessie, Derikx, Lauranne A A P, Dunlop, Allan, Greathead, Louise, Griffiths, Rachel L, Ibraheim, Hajir, Kelleher, Peter, Kok, Klaartje B, Lees, Charlie W, MacDonald, Jonathan, Sebastian, Shaji, Smith, Philip J, McDonald, Timothy J, Irving, Peter M, Powell, Nick, Kennedy, Nicholas A, Goodhand, James R, Ahmad, Tariq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499950/
https://www.ncbi.nlm.nih.gov/pubmed/34473254
http://dx.doi.org/10.1093/ecco-jcc/jjab153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499950/
https://www.ncbi.nlm.nih.gov/pubmed/34473254
http://dx.doi.org/10.1093/ecco-jcc/jjab153

Ejemplares similares